Hemcheck Sweden AB and Hospital de la Santa Creu i Sant Pau have successfully finalized two studies at the ICU and the Biochemistry department.
The first in the ICU was set up to evaluate the frequency of hemolyzed blood samples intended for blood gas analysis and its effect on clinical decision making. The second in the Biochemistry department was set up to evaluate the performance and time saving of Hemcheck’s system versus using the laboratory’s clinical chemistry analyser to detect hemolysis.
The main result from the first study in the ICU is that over 900 blood gas samples in syringes have been included and that hemolyzed blood samples are frequent, up to ca 8%, and they showed higher potassium levels than non-hemolyzed samples.
The main result from the second study is that over 800 blood samples in vacuum tubes have been included, that there is a large time saving of around 40 minutes using Hemcheck’s system for detecting hemolysis also within the laboratory compared to the reference method, and that Hemcheck’s system has showed performance levels well above the performance claims of the system.
–It is very positive that we have concluded these studies with such good results, since it gives additional evidence on the issues of hemolysis in blood gas analysis and on the value with using our system. We look forward to continuing the collaboration with Sant Pau and detail the results in a scientific article, says Joen Averstad, CEO of Hemcheck.
– We are very satisfied with the studies and the results are really interesting. It shows the importance of the pre-analytical phase and the potential improvements that can be made with early hemolysis detection, including more accurate results and time and cost savings. We will now discuss how to move forward in publicizing the results and potential further collaborations with Hemcheck, says Dr Jorge Ordonez-Llanos, Professor of Clinical Biochemistry and coordinator of the study.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About Hospital de la Santa Creu i Sant Pau
Hospital de la Santa Creu i Sant Pau is the oldest hospital in Spain. Its activities focus on Barcelona but extend to the rest of Catalonia. The centre plays a prominent role at a Spanish level and is internationally renowned. It has around 550 beds and treats ca 160 000 acute patients, 460 000 outpatients and ca 36 000 inpatients per year. In the field of research, the Hospital de la Santa Creu i Sant Pau is one of the leading centres in Spain.
Read more at: http://www.santpau.cat/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolyzed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolyzed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on April 20, 2021 at 16.00